mek 4

MEK4 inhibitor-1 is a newly developed compound specifically designed to inhibit the activity of MEK4, a key enzyme involved in pancreatic adenocarcinoma, with an IC 50 value of 61 nM.

MEK4 IN-3 (Compound 39) is a selective MEK4 inhibitor with IC50 values of 78 nM for MEK4 and 2920 nM for RSK4. MEK4 IN-3 can reduce cytotoxicity and is applicable in research concerning liver failure, particularly in studies of non-alcoholic fatty liver disease (NAFLD).

MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.

MEK-IN-4 is a MEK inhibitor utilized in the study of inflammatory diseases and cancer.

PAK1-IN-2 (Compound 35) is a selective PAK1 inhibitor with a Ki of 7.3 nM. It inhibits MEK phosphorylation and shows significant inhibitory effects on cancer cell lines with amplified PAK1/4. PAK1-IN-2 is applicable in tumor research.

BI-847325 is a selective dual inhibitor of MEK and aurora kinases (AK) with IC50 values of 4 and 15 nM for human MEK2 and AK-C, respectively.

1. Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways. 2. Nardosinone could protect against the neuronal injury exposed to OGD, which may be relevant to the

CML-IN-1, also known as compound 7 and compound 4, is a potent anticancer agent that demonstrates a strong induced-apoptosis effect in the human chronic myeloid leukemia (CML) cell line K562. It diminishes protein phosphorylation within the PI3K/Akt signaling pathway to exert its effects and suppresses cell proliferation through the inhibition of the MEK/ERK signaling pathway in colorectal cancer [1] [2].

Zapnometinib (ATR-002) is a MEK inhibitor.

Nardosinone (Standard) is a reference standard for research and analysis in studies involving Nardosinone. 1. Nardosinone has inhibitory effect on Ang II-induced hypertrophy in H9c2 cells, might be mediated by targeting PI3K/Akt and MEK/ERK signaling pathways. 2. Nardosinone could protect against the neuronal injury exposed to OGD, which may be relevant to the promotion of PKA and ERK signaling pathway. 3. Nardosinone enhances staurosporine- or dbcAMP-induced neurite outgrowth from PC12D cells, probably by amplifying both the MAP kinase-dependent and -independent signaling pathways of dbcAMP and staurosporine. 4. The enhancement of NGF-induced neurite outgrowth from PC12D cells by Nardosinone involves activation of a down-stream step of the MAP kinase-dependent cascade of NGF coupled with PKC.